Related Experiment Video

Updated: Jun 12, 2026

Mouse Model of Acute to Chronic Kidney Disease Transition Induced by Renal Ischemia/Reperfusion Injury
07:02

Mouse Model of Acute to Chronic Kidney Disease Transition Induced by Renal Ischemia/Reperfusion Injury

Published on: February 10, 2026

Association between IGF-1 and chronic kidney disease among US adults

Srinivas Teppala1, Anoop Shankar, Charumathi Sabanayagam

  • 1Department of Community Medicine, West Virginia University School of Medicine, P.O. Box 9190, Morgantown, WV 26506-9190, USA.

Clinical and Experimental Nephrology
|June 23, 2010
PubMed

Insights

Higher insulin-like growth factor (IGF-1) levels are linked to increased odds of chronic kidney disease (CKD) in US adults. This study suggests IGF-1 may be a potential predictor for CKD development.

Area of Science:

  • Endocrinology
  • Nephrology
  • Public Health

Background:

  • Insulin-like growth factor (IGF-1) is implicated in cardiovascular disease, hypertension, and diabetes.
  • The relationship between IGF-1 and chronic kidney disease (CKD) has not been previously investigated.

Purpose of the Study:

  • To examine the association between serum IGF-1 levels and the prevalence of CKD.
  • To determine if IGF-1 could serve as a predictor for CKD in a US adult population.

Main Methods:

  • Cross-sectional study utilizing data from 5388 participants (aged ≥20 years) in the Third National Health and Nutrition Examination Survey (NHANES III).
  • Serum IGF-1 levels were stratified into quartiles.
  • CKD was defined as an estimated glomerular filtration rate <60 mL/min/1.73/m² (n=241).

Main Results:

  • Higher serum IGF-1 levels demonstrated a positive association with CKD.
  • After adjusting for multiple covariates, the highest quartile (quartile 4) of IGF-1 showed an odds ratio of 2.66 (95% CI: 1.18-5.99) for CKD compared to the lowest quartile (quartile 1).
  • A significant trend (p=0.008) indicated increasing CKD risk with higher IGF-1 quartiles, consistent across gender subgroups.

Conclusions:

  • Elevated serum IGF-1 levels are significantly associated with an increased prevalence of CKD in US adults.
  • IGF-1 may represent a novel biomarker for predicting CKD risk, particularly in Western populations.
  • Further research is warranted to elucidate the underlying mechanisms linking IGF-1 to kidney disease.
Abstract

More Related Videos

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...